The Silent Killer — How Poor Cybersecurity Can Halt Market Entry | LSI USA '25

 Moderator Christian Espinosa from Blue Goat Cyber discuss how weak cybersecurity measures can critically delay or prevent medtech companies from successfully entering the market. For more information watch this video: https://www.youtube.com/watch?v=5Uc1lSvDNBk

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Memo | Special Edition: Medtech Trailblazers Heading to LSI USA '26

Each week in The Memo , we spotlight one emerging medtech company pushing the boundaries of what’s possible in patient care. This week, we’re doing something different. With LSI USA ’26 just two weeks away, we’re featuring a special edition highlighting a select group of trailblazing companies across five major market segments, all of whom will take the stage in Dana Point. This is only a snapshot of the companies presenting at LSI USA ’26, but it offers a compelling preview of the innovation that will be on display. *Note: All information included in this article is sourced from the LSI USA ’26 Startup Profiles spreadsheet, Compass AI , and the LSI USA ’26 Presenting Companies page . Cardiovascular Fluid Biomed Presenter : John Wong Company Description : Fluid Biomed is developing the world’s first bioabsorbable stent to treat brain aneurysms. The company’s innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficien...
Read more